Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.60 |
| ▸ | NAAA | Q02083 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200673 | 1.00 | CRBN (0.60) | CRBNDDB1NAAAALDH1A1GAA | |
| SCHEMBL632914 | 1.00 | CRBN (0.60) | CRBNDDB1NAAAALDH1A1GAA | |
| SCHEMBL1903249 | 0.90 | CRBN (0.53) | CRBNDDB1NAAAALDH1A1GAA | |
| SCHEMBL5180974 | 0.87 | NAAA (0.58) | NAAAALDH1A1GAATSHRASAH1 | |
| SCHEMBL3930648 | 0.87 | NAAA (0.58) | NAAAALDH1A1GAATSHRASAH1 | |
| SCHEMBL765661 | 0.87 | NAAA (0.58) | NAAAALDH1A1GAATSHRASAH1 | |
| SCHEMBL19207870 | 0.85 | RIPK1 (0.57) | NAAAALDH1A1GAATSHR | |
| SCHEMBL1976229 | 0.85 | RIPK1 (0.57) | NAAAALDH1A1GAATSHR | |
| SCHEMBL7426649 | 0.85 | RIPK1 (0.57) | NAAAALDH1A1GAATSHR | |
| SCHEMBL425375 | 0.82 | ALDH1A1 (0.58) | NAAAALDH1A1GAATSHRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353672-B1 | SYNTHESIS OF 4-AMINO-THALIDOMIDE ENANTIOMERS | CHILDRENS MEDICAL CENTER (US) | 2007-10-03 | — | — | EP | claimed |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2017134476-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2017-08-10 | — | — | WO | disclosed |
| US-9694015-B2 | Methods for the treatment of locally advanced breast cancer | CELGENE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160319005-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2016-11-03 | — | — | US | disclosed |
| US-9365640-B2 | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | CELGENE CORPORATION (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2892537-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | Celgene Corporation (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014110322-A2 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014039960-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | CELGENE CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
| EP-2702410-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | Celgene Corporation (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2012-12-20 | — | — | US | disclosed |
| WO-2012149299-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORAITON (US) | 2012-11-01 | — | — | WO | disclosed |
| US-7812169-B2 | Method of synthesis of 4-amino-thalidomide enantiomers | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1353672-B1 | SYNTHESIS OF 4-AMINO-THALIDOMIDE ENANTIOMERS | CHILDRENS MEDICAL CENTER (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319005-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | CRBN 1/4885DDB1 946/4885NAAA 3874/4885 |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | CRBN 1/4885DDB1 946/4885NAAA 3874/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CRBN 286/4885DDB1 1415/4885NAAA 1888/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885NAAA 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.